Richard Meelia, the outgoing CEO of Covidien plc (NYSE:COV), is re-joining the board of directors at Haemonetics Corp. (NYSE:HAE) two years after stepping down to focus on Covidien.
Meelia, who plans to retire from Covidien’s corner office July 1 (he’ll stay on as non-executive chairman for the Mansfield, Mass.-based medical products maker), served on Haemonetics’ board from 2005 through 2009.
The now-62-year-old Meelia resigned his seat, the company said at the time, “in order to spend more professional time on Covidien’s operations," which were smack in the middle of a major restructuring. He has a big-league pedigree from nearly 40 years in the health care trenches, including stints leading Covidien pre-cursors Tyco Healthcare and Kendal Healthcare Products.
"I look forward to rejoining the Haemonetics Board of Directors and serving the Company’s shareholders," Meelia said in prepared remarks. "Brian and his team have done a terrific job in growing the business and I believe Haemonetics is well-positioned to succeed going forward."
In March, Covidien announced that it named the head of its medical device arm, José Almeida, to replace Meelia. Almeida is the headliner at the MassDevice Big 100 Regional Roundtable slated for July 11.
Systagenix shuffles the deck at CEO
Systagenix Wound Management named Ernest Waaser as CEO, replacing Steve Atkinson, who’s led the firm since it was spun out of Johnson & Johnson’s (NYSE:JNJ) advanced wound care business in 2008.
Back in October 2009, Atkinson told MassDevice that the company planned to revitalize the product development pipeline that had gone slack at J&J. Late last year, Systagenix inked a deal with ECI Biotech to develop a point-of-care diagnostic for infections of chronic wounds.